Gateway for:

Member Countries

Anti-Legionellosis Vaccine


Development of Live Recombinant Vaccine Against Legionellosis

Tech Area / Field

  • BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology
  • BIO-MIB/Microbiology/Biotechnology
  • MED-VAC/Vaccines/Medicine

8 Project completed

Registration date

Completion date

Senior Project Manager
Evstyukhin K N

Leading Institute
State Research Center for Applied Microbiology, Russia, Moscow reg., Obolensk


  • FOA National Defence Research Establishment, Sweden, Stockholm

Project summary

Development of experimantal samples of live vaccine against legionellosis on the base of Francisella tularensis recombinant vaccine strains synthesining protective antigenes of is Legionella pneumophila the major goal of the project proposed.

The following problems to realise the project properly should be solved :

- to identify and study L.pneumophila antigenes which seems to be promising for the construction of F. tularensis recombinant strains;

- to select appropriate test systems for L. pneumophila antigenes;

- to perform the cloning of L. pneumophila genes encoding the protective antigenes;

- to develop vector systems providing the transition, expression and stable inheriting; of legionella genes in the cells of F. tularensis;

- to construct recombinant strains of F. tularensis synthesizing protective antigenes of L. pneumophila;

- to study immune and biological properties of the recombinant strains obtaind by using the model of legionellosis infection;

- to select the recombinant strains of F. tularensis promising as the experimental samples of the vaccine

It is expected that protective antigenes of L.pneumophila will be identified a characterized, their encoding genes will be cloned, and recombinant strains of F. tularensis for the legionellosis antigenes production will be constructed as a result of the investigatic The strains promissing as experimetal samples of vaccines will be selected on the basis of immunobiological properties; the experimental samples of antilegionellosis vaccines will created.

The realization of the project proposed should yield a novel approach to the construc-tion polyvalent recombinant live vaccines on the base of the vaccine against tularemia, that general seems to be a new trend in the construction of live recombinant vaccin Experimental data obtained will be published and extend the knowlege of scientists in field of immunology and genetics of L. pneumophila and F. tularensis. The experimental vaccine samples will be used in medicine practice for tprevention of Legionaires1 disease.

Our recent studies on the optimization of the method of F. Tularensis transformatio construction of the vector plasmids on the basis of natural plasmide isolated from. novicida like strain F5969, construction of F. tularensis strains synthesizing protective antigenes of bacilla as well as the set of the cloned L. pneumophila genes encoding legionellosis antigenes should assist us in solving the problems in hand.

The project proposals address the objectives of ISTC in providing weapons scientist a: engineers opportunities to redirect their talents to peaceful activities. In particular, the experimental antilegionellosis vaccine can be used for medicine and health care needs.


The International Science and Technology Center (ISTC) is an intergovernmental organization connecting scientists from Kazakhstan, Armenia, Tajikistan, Kyrgyzstan, and Georgia with their peers and research organizations in the EU, Japan, Republic of Korea, Norway and the United States.


ISTC facilitates international science projects and assists the global scientific and business community to source and engage with CIS and Georgian institutes that develop or possess an excellence of scientific know-how.

Promotional Material

Значимы проект

See ISTC's new Promotional video view